Beta-Arrestin1 Prevents Preeclampsia by Downregulation of Mechanosensitive AT1-B2 Receptor Heteromers.

Preeclampsia is the most frequent pregnancy-related complication worldwide with no cure. While a number of molecular features have emerged, the underlying causal mechanisms behind the disorder remain obscure. Here, we find that increased complex formation between angiotensin II AT1 and bradykinin B2, two G protein-coupled receptors with opposing effects on blood vessel constriction, triggers symptoms of preeclampsia in pregnant mice. Aberrant heteromerization of AT1-B2 led to exaggerated calcium signaling and high vascular smooth muscle mechanosensitivity, which could explain the onset of preeclampsia symptoms at late-stage pregnancy as mechanical forces increase with fetal mass. AT1-B2 receptor aggregation was inhibited by beta-arrestin-mediated downregulation. Importantly, symptoms of preeclampsia were prevented by transgenic ARRB1 expression or a small-molecule drug. Because AT1-B2 heteromerization was found to occur in human placental biopsies from pregnancies complicated by preeclampsia, specifically targeting AT1-B2 heteromerization and its downstream consequences represents a promising therapeutic approach.

A cleavable signal peptide enhances cell surface delivery and heterodimerization of Cerulean-tagged angiotensin II AT1 and bradykinin B2 receptor.

Heterodimerization of the angiotensin II AT1 receptor with the receptor for the vasodepressor bradykinin, B2R, is known to sensitize the AT1-stimulated response of hypertensive individuals in vivo. To analyze features of that prototypic receptor heterodimer in vitro, we established a new method that uses fluorescence resonance energy transfer (FRET) and applies for the first time AT1-Cerulean as a FRET donor. The Cerulean variant of the green fluorescent protein as donor fluorophore was fused to the C-terminus of AT1, and the enhanced yellow fluorescent protein (EYFP) as acceptor fluorophore was fused to B2R. In contrast to AT1-EGFP, the AT1-Cerulean fusion protein was retained intracellularly. To facilitate cell surface delivery of AT1-Cerulean, a cleavable signal sequence was fused to the receptor's amino terminus. The plasma membrane-localized AT1-Cerulean resembled the native AT1 receptor regarding ligand binding and receptor activation. A high FRET efficiency of 24.7% between membrane-localized AT1-Cerulean and B2R-EYFP was observed with intact, non-stimulated cells. Confocal FRET microscopy further revealed that the AT1/B2 receptor heterodimer was functionally coupled to receptor desensitization mechanisms because activation of the AT1-Cerulean/B2R-EYFP heterodimer with a single agonist triggered the co-internalization of AT1/B2R. Receptor co-internalization was sensitive to inhibition of G protein-coupled receptor kinases, GRKs, as evidenced by a GRK-specific peptide inhibitor. In agreement with efficient AT1/B2R heterodimerization, confocal FRET imaging of co-enriched receptor proteins immobilized on agarose beads also detected a high FRET efficiency of 24.0%. Taken together confocal FRET imaging revealed efficient heterodimerization of co-enriched and cellular AT1/B2R, and GRK-dependent co-internalization of the AT1/B2R heterodimer.

Establishment of an in vivo model facilitates B2 receptor protein maturation and heterodimerization.

In individuals with diverse cardiovascular risk factors, signalling stimulated by the AT(1) receptor for the vasopressor angiotensin II is sensitized by heterodimerization with the receptor for the vasodepressor bradykinin, B(2). Signal sensitization and receptor heterodimerization rely on efficient maturation of the B(2) receptor protein. To assess functional features of that important cardiovascular receptor system, we established an in vivo model by using immunodeficient NOD.Scid mice for the expansion of transfected cells under physiological conditions. Compared to cultivated cells, the in vivo model strongly facilitated B(2) receptor maturation and heterodimerization. To elucidate the mechanisms underlying the enhancement of B(2) receptor protein maturation under in vivo conditions, we performed microarray gene expression profiling. Microarray analysis revealed a more than 1.7-fold up-regulation of the chaperone calreticulin upon in vivo cell expansion whereas other important members of the general chaperone system were only marginally altered. Down regulation of calreticulin expression by RNA interference confirmed the importance of calreticulin for efficient B(2) receptor maturation under in vivo conditions. Receptor proteins synthesized in the Nod.Scid cell expansion model were functionally active and sensitive to drug treatment as exemplified by treatment with the AT(1)-specific antagonist losartan. Thus, we established a model system that can be used to analyze functional features of proteins in vivo by expanding transfected cells in immunodeficient NOD.Scid mice.